Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients ≥ 18 years of age without prior history of deferasirox treatment
β-thalassemia patients receiving regular transfusions every 2-5 weeks
Transfusion history of ≥ 20 units of packed red blood cells
Abnormal renal function at baseline
ALT greater than 5 x ULN at screening
Patients with underlying cardiac disease requiring continuous iron chelation therapy
Other protocol-defined inclusion/exclusion criteria may apply.